This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2002 Dec 10;99(25):15840-2.

doi: 10.1073/pnas.262669499. Epub 2002 Dec 2.

T cells take aim at cancer

Affiliations

PMID: 12461164
PMCID: PMC138522
DOI: 10.1073/pnas.262669499

Comment

T cells take aim at cancer

Drew Pardoll. Proc Natl Acad Sci U S A. 2002.

. 2002 Dec 10;99(25):15840-2.

doi: 10.1073/pnas.262669499. Epub 2002 Dec 2.

Author

Affiliation

¹ Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.

PMID: 12461164
PMCID: PMC138522
DOI: 10.1073/pnas.262669499

No abstract available

PubMed Disclaimer

Figures

Fig 1. — Fig 1.
T cell recognition of cancer. In this scanning electron micrograph, a tumor-specific CD8+ killer T cell is shown in the act of recognizing a tumor cell expressing the cognate tumor antigen (arrow). Multiple other T cells not specific for any tumor antigens ignore the tumor cell. Tumor antigen recognition first involves generation of a tight junction with the tumor cell after which perforin is released to create pores in the tumor target. Granzymes released by the killer T cell can enter the cytoplasm of the tumor via these pores and activate effector caspases to induce apoptosis. (Magnification: ×5,000.)

See this image and copyright information in PMC

Comment on

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Yee C, et al. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73. doi: 10.1073/pnas.242600099. Epub 2002 Nov 11. Proc Natl Acad Sci U S A. 2002. PMID: 12427970 Free PMC article. Clinical Trial.

Similar articles

Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.
Strome SE, Krauss JC, Chang AE, Shu S. Strome SE, et al. J Hematother. 1993 Spring;2(1):63-73. doi: 10.1089/scd.1.1993.2.63. J Hematother. 1993. PMID: 7921967 Review. No abstract available.
Genetically engineered T cells as adoptive immunotherapy of cancer.
Ma Q, Gonzalo-Daganzo RM, Junghans RP. Ma Q, et al. Cancer Chemother Biol Response Modif. 2002;20:315-41. Cancer Chemother Biol Response Modif. 2002. PMID: 12703212 Review. No abstract available.
Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes.
Whiteside TL, Heo DS, Takagi S, Herberman RB. Whiteside TL, et al. Immunol Ser. 1989;48:139-57. Immunol Ser. 1989. PMID: 2488318 No abstract available.
Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2.
Nakamura Y, Wakimoto H, Abe J, Kanegae Y, Saito I, Aoyagi M, Hirakawa K, Hamada H. Nakamura Y, et al. Cancer Res. 1994 Nov 15;54(22):5757-60. Cancer Res. 1994. PMID: 7525049
Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.
Besser MJ, Schallmach E, Oved K, Treves AJ, Markel G, Reiter Y, Schachter J. Besser MJ, et al. Cytotherapy. 2009;11(2):206-17. doi: 10.1080/14653240802590391. Cytotherapy. 2009. PMID: 19148842

See all similar articles

Cited by

Fever therapy revisited.
Hobohm U. Hobohm U. Br J Cancer. 2005 Feb 14;92(3):421-5. doi: 10.1038/sj.bjc.6602386. Br J Cancer. 2005. PMID: 15700041 Free PMC article. Review.
Impact of the immune system and immunotherapy in colorectal cancer.
Markman JL, Shiao SL. Markman JL, et al. J Gastrointest Oncol. 2015 Apr;6(2):208-23. doi: 10.3978/j.issn.2078-6891.2014.077. J Gastrointest Oncol. 2015. PMID: 25830040 Free PMC article. Review.
Combination immunotherapy approaches.
Drake CG. Drake CG. Ann Oncol. 2012 Sep;23 Suppl 8(Suppl 8):viii41-6. doi: 10.1093/annonc/mds262. Ann Oncol. 2012. PMID: 22918927 Free PMC article. Review.
A mathematical model of immune-system-melanoma competition.
Pennisi M. Pennisi M. Comput Math Methods Med. 2012;2012:850754. doi: 10.1155/2012/850754. Epub 2012 Jun 3. Comput Math Methods Med. 2012. PMID: 22701144 Free PMC article.
Anticancer and immunostimulatory activity by conjugate of paclitaxel and non-toxic derivative of LPS for combined chemo-immunotherapy.
Roy A, Chandra S, Mamilapally S, Upadhyay P, Bhaskar S. Roy A, et al. Pharm Res. 2012 Aug;29(8):2294-309. doi: 10.1007/s11095-012-0756-y. Epub 2012 May 1. Pharm Res. 2012. PMID: 22547032

See all "Cited by" articles

References

1. Yee C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E. & Greenberg, P. D. (2002) Proc. Natl. Acad. Sci. USA 99, 16168-16173. - PMC - PubMed
1. Dudley M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) Science 298, 850-854. - PMC - PubMed
1. Pardoll D. M. (2002) Nat. Rev. Immunol. 2, 227-238. - PubMed
1. Boon T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P. & Van Pel, A. (1994) Annu. Rev. Immunol. 12, 337-365. - PubMed
1. Levitsky H. I. (2000) Cancer J. 3, S281-S290. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database